Ranitadine
(Zantac) |
Category:
Description:
Indications:
-
Duodenal
ulcer; benign gastric ulcer
-
Pathological
hypersecretory conditions (Zollinger-Ellison syndrome)
-
Gastroesophageal
reflux disease (GERD)
-
Erosive
gastritis
-
Stress
ulcer prophylaxis
Drug
Interactions:
-
Reduced
efficacy: cefuroxine,
cefpodoxime
-
Enhanced
hypoglycemic effect: glipizide
-
Increased
bioavailability: nifedipine,
nitrendipine, nisoldipine
-
Decreased
plasma concentrations: ketoconazole,
enoxacin
Precautions:
Adverse
Reactions (Side Effects):
-
CNS:
dizziness, insomnia, malaise, somnolence, vertigo
-
CV:
atrioventricular block, bradycardia, premature ventricular beats,
tachycardia
-
GI:
Abdominal discomfort or pain, constipation, hepatitis, increased liver
function tests, nausea, vomiting, pancreatitis (rare)
-
HEME:
granulocytopenia, leukopenia, thrombocytopenia
-
SKIN:
alopecia, erythema multiforme (rare), rash
-
MS:
arthralgias, myalgias
|
Dosage:
Administered
PO (tablets, gelatin capsules, syrup), IV, and IM
-
Adult:
-
Duodenal
and gastric ulcer: PO 150mg twice daily or 300mg at bedtime
for 4-8 weeks, maintenance 150mg every night at bedtime
-
GERD:
-
Erosive
esophagitis:
-
Pathological
hypersecretory conditions:
-
PO
150mg twice daily initially, titrate to desired response up to
6 grams daily
-
IV
INF start 1mg/kg/hr, increase by 0.5mg/kg/hr intervals every 4
hours as needed up to 2.5mg/kg/hr
-
IM/IV
50mg every 6 to 8 hours, do not exceed 400mg per day;
-
IV
INF 6.25mg/hr
-
Child:
-
PO
1.25mg/kg every 12 hours, max 300mg/kg/day
-
IM/IV
0.75-1.5mg/kg every 6-8 hours, max 6mg/kg/day or 300mg/day
-
IV
INF 0.1-0.25mg/kg/hr
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|